Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome?

Clinical and Experimental Rheumatology

Volumn 31, Issue 6, 2013, Pages 926-932

  Berman, Horacio ^a   Ugarte Gil, Manuel F ^a   Espinosa, Gerard ^a   Tàssies, Dolors ^a   Monteagudo, Joan ^a   Reverter, Joan Carles ^a   Cervera, Ricard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Antiphospholipid syndrome; Factor V leiden; Inherited thrombophilia; Prothrombin polymorphism; Recurrent thrombosis

Indexed keywords

ALANINE; BLOOD CLOTTING FACTOR 5 LEIDEN; GLYCINE; PROTHROMBIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FACTOR V LEIDEN GENE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INHERITANCE; LOWER EXTREMITY DEEP VEIN THROMBOSIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTHROMBIN GENE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHILIA;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANTIPHOSPHOLIPID SYNDROME; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; PREVALENCE; PROGNOSIS; PROTHROMBIN; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SPAIN; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84892468824     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. MIYAKIS S, LOCKSHIN MD, ATSUMI T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. LOVE PE, SANTORO SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682-98.
3. GINSBERG JS, WELLS PS, BRILL-EDWARDS P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-91.
4. CERVERA R, PIETTE JC, FONT J, et al. for the Euro-Phospholipid Project Group: Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-27.
5. MOK CC, TANG SS, TO CH, PETRI M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005; 52: 2774-82.
6. ROLDAN V, LECUMBERRI R, MUNOZ-TORRERO JF, et al. RIETE Investigators. Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. Thromb Res 2009; 124: 174-7.
7. BUSHNELL CD, GOLDSTEIN LB. Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke 2000; 31: 3067-78.
8. TEKTONIDOU MG, LASKARI K, PANAGIOTAKOS DB, MOUTSOPOULOS HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61: 29-36.
9. DANOWSKI A, de AZEVEDO MN, de SOUZA PAPI JA, PETRI M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009; 36: 1195-9.
10. RUFFATTI A, DEL ROSS T, CIPRIAN M, et al. Antiphospholipid Syndrome Study Group of Italian Society of Rheumatology. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011; 70: 1083-6.
11. KYRLE PA, EICHINGER S. Deep vein thrombosis. Lancet 2005; 365: 1163-74.
12. MARCHIORI A, MOSENA L, PRINS MH, PRANDONI P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 2007; 92: 1107-14.
13. CASTRO-MARRERO J, BALADA E, VILAR-DELL-TARRES M, ORDI-ROS J. Genetic risk factors of thrombosis in the antiphospholipid syndrome. Br J Haematol 2009; 147: 289-96.
14. BOKAREWA MI, BREMME K, FALK G, STEN-LINDER M, EGBERG N, BLOMBACK M. Studies on phospholipid antibodies, APC resistance and associated mutation in the coagulation factor V gene. Thromb Res 1995; 3: 193- 200.
15. MONTARULI B, BORCHIELLINI A, TAMPONI G, et al. Factor V Arg506-Gln mutation in patients with antiphospholipid antibodies. Lupus 1996; 5: 303-6.
16. SIMANTOV R, LO SK, SALMON JE, SAMMARITANO LR, SILVERSTEIN RL. Factor V Leiden increases the risk of thrombosis in patients with antiphospholipid antibodies. Thromb Res 1996; 84: 361-5.
17. GALLI M, FINAZZI G, DUCA F, NORBIS F, MOIA M. The G1691-A mutation of factor V, but not the G20210-A mutation of factor II or the C677-T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants. Br J Haematol 2000; 108: 865- 70.
18. BROUWER JLP, BIJL M, VEEGER NJ, KLUIN-NELEMANS HC, van der MEER J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004; 104: 143-8.
19. PABLOS JL, CALIZ RA, CARREIRA PE, et al. Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation. J Rheumatol 1999; 26: 588-90.
20. TORRESAN M, MACHADO TF, SIQUEIRA LH, OZELO MC, ARRUDA VR, ANNICHINO-BIZZACCHI JM. The impact of the search for thrombophilia risk factors among antiphospholipid syndrome patients with thrombosis. Blood Coagul Fibrinolysis 2000; 11: 679-82.
21. SALLAI KK, NAGY E, BODÓ I, MOHL A, GERGELY P. Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors. Scand J Rheumatol 2007; 36: 198- 205.
22. BIOUSSE V, PIETTE JC, FRANCES C, et al. Primary antiphospholipid syndrome is not associated with activated protein C resistance caused by factor V Arg 506-Gln mutation. J Rheumatol 1995; 22: 1215.
23. DAVIES K, IRELAND H, ATHANASSIOU P, LOIZOU S, LANE D, WALPORT MJ. Factor V Leiden and venous thrombosis. Lancet 1995; 345: 132-3.
24. DIZON-TOWNSON D, HUTCHISON C, SILVER R, BRANCH DW, WARD K. The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome. Thromb Haemost 1995; 74: 1029-31.
25. FORASTIERO R, MARTINUZZO M, ADAMCZUK Y, VARELA ML, POMBO G, CARRERAS LO. The combination of thrombophilic genotypes is associated with definite antiphospholipid syndrome. Haematologica 2001; 86: 735-41.
26. CHOPRA N, KOREN S, GREER WL, et al. Factor V Leiden, prothrombin gene mutation, and trombosis risk in patients with antiphospholipid antibodies. J Rheumatol 2002; 29: 1683-8.
27. BENTOLILA S, RIPOLL L, DROUET L, CRASSARD I, TOURNIER-LASSERVE E, PIETTE JC. Lack of association between thrombosis in primary antiphospholipid syndrome and the recently described thrombophilic 3'-untranslated prothrombin gene polymorphism. Thromb Haemost 1997; 78: 1415.
28. BERTOLACCINI ML, ATSUMI T, HUNT BJ, AMENGUAL O, KHAMASHTA MA, HUGHES GR. Prothrombin mutation is not associated with thrombosis in patients with antiphospholipid syndrome. Thromb Haemost 1998; 80: 202-3.
29. RUIZ-ARGÜELLES GJ, GARCES-EISELE J, RUIZ-DELGADO GJ, ALARCÓN-SEGOVIA D. The G20210A polymorphism in the 3'-untranslated region of the prothrombin gene in Mexican mestizo patients with primary antiphospholipid syndrome. Clin Appl Thromb Haemost 1999; 5: 158-60.
30. TAN EM, COHEN AS, FRIES JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
31. POORT SR, ROSENDAAL FR, REITSMA PH, BERTINA RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
32. BRANDT JT, TRIPLETT DA, ALVING B, SCHARRER I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-90.
33. REVERTER JC, TÀSSIES MD. Genetic aspects of the antiphospholipid syndrome: association with clinical manifestations. Amsterdam: Elsevier; 2009. p. 91-103.
34. KATZAV A, GRIGORIADIS NC, EBERT T, et al. Coagulopathy triggered autoimmunity: experimental antiphospholipid syndrome in factor V Leiden mice. BMC Medicine 2013; 11: 92.
35. TASSIES D, ESPINOSA G, MUNOZ-RODRIGUEZ FJ, et al. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 2000; 43: 2349-58.
36. DIZ-KUCUKKAYA R, HANCER VS, ARTIM-ESEN B, PEKCELEN Y, INANC M. The pre-valence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome. J Thromb Thrombolysis 2010; 29: 303-9.
37. BERKUN Y, PADEH S, BARASH J, et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Care Res 2006; 55: 850-5.
38. AMES PR, CIAMPA A, MARGAGLIONE M, SCENNA G, IANNACCONE L, BRANCACCIO V. Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation: an 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia. Thromb Haemost 2005; 93: 694-9.
39. th International Congress on Antiphospholipid Antibodies. Lupus 2011; 20: 206-18.
40. HERNANDEZ-MOLINA G, ESPERICUETA-ARRIOLA G, CABRAL AR. The role of lupus anticoagulant and triple marker positivity as risk factors for rethrmbosis in patients with primary antiphospholipid syndrome. Clin Exp Rheumatol 2013; 31: 382-8